What's New in Eczema Management: Practice Pearls for the Family Physician

Primary care physicians, Family physicians, Pediatricians

Activity Information

Credits: 0.50 AAFP Prescribed Credit(s)
Launch Date: April 30, 2020
Expiration Date: April 30, 2021

COURSE FACULTY

Anthony J. Mancini, MD, FAAP, FAAD
Head, Division of Pediatric Dermatology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Dermatology
Northwestern University Feinberg School of Medicine
Chicago, IL

LEARNING OBJECTIVES

  1. Recognize the clinical features and characteristic age distribution patterns of atopic dermatitis (AD)     
  2. Describe the role of skin barrier dysfunction, immune dysregulation, and environmental factors in the pathogenesis of AD
  3. Individualize AD management regimens according to age, location, disease severity, response to treatment, and quality-of-life (QOL) concerns
  4. Educate patients and families about the safe and appropriate use of skin-directed therapies for the treatment of AD

COURSE INFORMATION

SPONSORSHIP & SUPPORT
This educational activity is jointly provided by the North Carolina Academy of Family Physicians (NCAFP) and Spire Learning.
 

This activity is supported by an educational grant from Pfizer Inc.

PROGRAM OVERVIEW
This case activity addresses the latest in the care and management of atopic dermatitis and provides expert insights on creating a personalized, holistic management plan to improve disease control and quality of life for your patients and their caregivers.

TARGET AUDIENCE
Family physicians

LEARNING OBJECTIVES
Upon completion of this educational activity, learners should be better able to:

    RECOGNIZE the clinical features and characteristic age distribution patterns of atopic dermatitis (AD)
    DESCRIBE the role of skin barrier dysfunction, immune dysregulation, and environmental factors in the pathogenesis of AD
    INDIVIDUALIZE AD management regimens according to age, location, disease severity, response to treatment, and quality-of-life (QOL) concerns
    EDUCATE patients and families about the safe and appropriate use of skin-directed therapies for the treatment of AD

ACCREDITATION AND DISCLAIMER STATEMENTS
This enduring activity, What’s New in Eczema Management: Practice Pearls for the Family Physician has been reviewed and is acceptable for up to 0.5 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
AMA/AAFP Equivalency:
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.
 
HOW TO RECEIVE CREDIT
To receive credit for your participation in this educational activity:

    Read the objectives and other introductory CME information
    Complete the preassessment prior to the start of the activity
    Participate in the atopic dermatitis (eczema) case activity
    Complete the postassessment and evaluation at the conclusion of the activity

If you are seeking Prescribed credit, you must complete the postassessment and evaluation at the conclusion of the activity.

LEVELS OF EVIDENCE
Levels of evidence are provided for any patient care recommendations made during this presentation.

Level A (randomized controlled trial/meta-analysis): High-quality, randomized controlled trial (RCT) that considers all important outcomes. High-quality meta-analysis (quantitative systematic review) using comprehensive search strategies

Level B (other evidence): A well-designed, nonrandomized clinical trial. A nonquantitative systematic review with appropriate search strategies and well-substantiated conclusions. Includes lower-quality RCTs, clinical cohort studies, and case-controlled studies with nonbiased selection of study participants and consistent findings. Other evidence, such as high-quality, historical, uncontrolled studies, or well-designed epidemiologic studies with compelling findings, is also included

Level C (consensus/expert opinion): Consensus viewpoint or expert opinion

Each rating is applied to a single reference in the presentation, not the entire body of evidence on the topic.

OFF-LABEL STATEMENT
The faculty does not discuss non–FDA-approved or investigational agents for the treatment of atopic dermatitis (eczema).

Participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.        

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above